Tema Cardiovascular and Metabolic ETF Price & Performance (HRTS)

Soleno Therapeutics announced FDA approval for VYKAT XR, an extended-release tablet for treating hyperphagia in Prader-Willi syndrome patients aged 4 and older. This marks the first-ever approved therapy for this condition, addressing a critical unmet need. The treatment is expected to be available in the U.S. from April 2025.1

BB Biotech AG's shareholders approved all board proposals at their recent AGM, including a CHF 1.80 per share dividend. The dividend will be paid on March 25, 2025, with the record date set for March 24. Board members were also re-elected for another term, reflecting strong investor confidence.2

The Tema Cardiovascular and Metabolic ETF (HRTS) has been downgraded to a sell candidate following a 1.12% price drop to $29.95. Analysts cite weak technical signals and low trading volume as key concerns, though the ETF is projected to rise modestly in the next three months under its current trend.3